Efficacy and Safety of Everolimus in de Novo Kidney Transplant Recipients of ECD or AKI Donors

Inclusion Criteria:

• Age 18-75 years
• Recipients of first DDKT from ECD or AKI donors
• Patient willing to participate in the study

Exclusion Criteria:

• Multi-organ recipients

  • Organ donation after Cardiac Death (DCD).
  • PRA > 20 % or with historical peak PRA > 50%
  • Patients who lost first graft due to immunological reason within the first year post-transplantation.
  • ABO incompatible transplants or positive cross-match
  • Patients with chronic inflammatory bowel disease.
  • Severe allergy requiring acute treatment, or any known hypersensitivity to everolimus, thymoglobulin
  • Thrombocytopenia (platelet < 75,000/mm3), ANC < 1,500 /mm3 or leucopenia (leucocytes < 2,500/mm3), or Hb < 6 g/dL
  • Chronic active HCV, HIV, or HBsAg positive
  • History of malignancy during the last five years, except squamous or basal cell carcinoma of the skin.
  • Ongoing infection requiring treatment with a systemic antibiotic.
  • Patient with severe hypercholesterolemia (> 300 mg/dL) or hypertriglyceridemia (> 600 mg/dL) that cannot be controlled
  • Evidence of severe liver disease.
  • Severe restrictive or obstructive pulmonary disorders.
  • Pregnant or nursing (lactating) women.
  • Patient who refuse to participate into the study or would like to withdraw from the study.